A Case of Favorable Responses after Gefitinib in a Patient with EGFR Mutated Adenosquamous Lung Carcinoma
Soonchunhyang Medical Science
; : 123-127, 2013.
Article
in English
| WPRIM (Western Pacific)
| ID: wpr-147411
Responsible library:
WPRO
ABSTRACT
In patients with advanced non-small cell lung cancer harboring epidermal growth factor receptor (EGFR) mutations, the epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are used as first treatment option. Because adenosquamous carcinoma (ASC) is a rare histologic subtype, evidences about EGFR-TKIs as first treatment option for advanced ASC are lacking. We report a case of an advanced ASC patient with the EGFR mutation, who showed good responses during 4-month treatment with gefitinib. And we will review about a necessity of EGFR mutation test and efficacy of EGFR-TKIs in ASC patients from the recent studies.
Full text:
Available
Database:
WPRIM (Western Pacific)
Main subject:
Phosphotransferases
/
Carcinoma, Adenosquamous
/
Carcinoma, Non-Small-Cell Lung
/
Epidermal Growth Factor
/
ErbB Receptors
/
Lung
Limits:
Humans
Language:
English
Journal:
Soonchunhyang Medical Science
Year:
2013
Document type:
Article